Head-to-head effectiveness and safety of pembrolizumab plus axitinib vs. nivolumab plus ipilimumab in metastatic renal cell carcinoma in the United States.

被引：0
|
作者：
Aran, Dvir
Granot-Hershkovitz, Einat
Amar-Farkash, Shlomit
Rosenberg-Katz, Keren
机构：
[1] Technion Israel Inst Technol, Fac Biol, Haifa, Israel
[2] Carelon Digital Platforms, Tel Aviv, Israel
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4532
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab plus axitinib vs. ipilimumab plus nivolumab
    Shah, Neil J.
    Sura, Sneha D.
    Shinde, Reshma
    Shi, Junxin
    Singhal, Puneet
    Perini, Rodolfo F.
    Motzer, Robert J.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (11) : 459.e1 - 459.e8
  • [2] Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US
    Watson, Tina R.
    Gao, Xin
    Reynolds, Kerry L.
    Kong, Chung Yin
    JAMA NETWORK OPEN, 2020, 3 (10)
  • [3] Clinical activity, immune and molecular correlates of nivolumab vs. nivolumab plus bevacizumab vs nivolumab plus ipilimumab in metastatic renal cell carcinoma
    Gao, Jianjun
    Karam, Jose A.
    Wood, Christopher G.
    Matin, Surena
    Ahrar, Kamran
    Jonasch, Eric
    Tannir, Nizar
    Campell, Matthew
    Ng, Chaan S.
    Slack, Rebecca S.
    Rao, Priya
    Allison, James P.
    Blando, Jorge M.
    Vence, Luis M.
    Basu, Sreyashi
    Zhao, Hao
    Chen, Tenghui
    Chen, Hong
    Sharma, Padmanee
    CANCER RESEARCH, 2017, 77
  • [4] Comparative cost-effectiveness analysis of avelumab plus axitinib versus pembrolizumab plus axitinib, ipilimumab plus nivolumab, and sunitnib for advanced renal cell carcinoma in the UK Perspective
    De Mello, Ramon Andrade
    Ayoub, Emili
    Castelo-Branco, Pedro
    De Almeida Zia, Victor Andre
    Savio, Andre
    Pozza, Daniel Humberto
    Tadokoro, Hakaru
    Teich, Nelson
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [5] A Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Versus Pembrolizumab Plus Axitinib and Versus Avelumab Plus Axitinib in First-Line Treatment of Advanced Renal Cell Carcinoma
    Shay, Rebecca
    Nicklawsky, Andrew
    Gao, Dexiang
    Lam, Elaine T.
    CLINICAL GENITOURINARY CANCER, 2021, 19 (04) : 370 - +
  • [6] COST-EFFECTIVENESS OF PEMBROLIZUMAB/AXITINIB AND NIVOLUMAB/IPILIMUMAB VERSUS SUNITINIB AS TREATMENT FOR ADVANCED RENAL CELL CARCINOMA IN THE UNITED STATES
    Yu, J. C.
    Gong, C.
    Zahoor, H.
    Hay, J. W.
    VALUE IN HEALTH, 2020, 23 : S381 - S382
  • [7] Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis
    Santoni, Matteo
    Rizzo, Alessandro
    Mollica, Veronica
    Rosellini, Matteo
    Marchetti, Andrea
    Fragomeno, Benedetta
    Battelli, Nicola
    Massari, Francesco
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (01) : 45 - 51
  • [8] Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma
    Zarrabi, Kevin K.
    Handorf, Elizabeth
    Miron, Benjamin
    Zibelman, Matthew R.
    Anari, Fern
    Ghatalia, Pooja
    Plimack, Elizabeth R.
    Geynisman, Daniel M.
    ONCOLOGIST, 2023, 28 (02): : 157 - 164
  • [9] Matching-adjusted indirect comparison of pembrolizumab plus axitinib versus nivolumab plus ipilimumab for the first-line treatment of advanced/metastatic renal cell carcinoma
    Wang, Yufei
    Zhong, Yichen
    Mt-Isa, Shahrul
    Perini, Rodolfo
    Adejoro, Oluwakayode
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [10] Pathologic complete response with pembrolizumab plus axitinib in metastatic renal cell carcinoma
    Shimizu, Kazuki
    Tamada, Satoshi
    Matsuoka, Yudai
    Go, Ishun
    Okumura, Satoshi
    Ogawa, Masao
    Ohmachi, Tetsuji
    INTERNATIONAL CANCER CONFERENCE JOURNAL, 2022, 11 (03) : 205 - 209
12345